FdaApplication
NDA 022192
Identifiers
- fda_app_no: NDA022192
Properties
| Property | Value |
|---|---|
| applicant_name | VANDA PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2009-05-06 |
Revenue by product
FANAPT
| Period | Revenue |
|---|---|
| Q2 2026 | $36.0M |
| Q1 2026 | $29.6M |
| Q4 2025 | $33.2M |
| Q3 2025 | $31.2M |
| Q2 2025 | $29.3M |
| Q1 2025 | $23.5M |
| Q4 2024 | $26.6M |
| Q3 2024 | $23.9M |
| Q2 2024 | $23.1M |
| Q1 2024 | $20.6M |
| Q4 2023 | $22.6M |
| Q3 2023 | $21.3M |
| Q2 2023 | $24.1M |
| Q1 2023 | $22.9M |
| Q4 2022 | $24.4M |
| Q3 2022 | $24.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (7)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| FANAPT | ILOPERIDONE | 4MG | TABLET;ORAL |
| FANAPT | ILOPERIDONE | 10MG | TABLET;ORAL |
| FANAPT | ILOPERIDONE | 2MG | TABLET;ORAL |
| FANAPT | ILOPERIDONE | 6MG | TABLET;ORAL |
| FANAPT | ILOPERIDONE | 12MG | TABLET;ORAL |
| FANAPT | ILOPERIDONE | 8MG | TABLET;ORAL |
| FANAPT | ILOPERIDONE | 1MG | TABLET;ORAL |
7 products